Sirnaomics Ltd. (Sirnaomics-B) reported a sharp reduction in interim net loss to USD0.38 million for the six months ended 30 June 2026, compared with a USD3.39 million loss a year earlier. The improvement stemmed from higher one-off gains, notably a USD6.00 million lease-termination gain, coupled with disciplined cost controls.
Other income rose 13% year on year to USD0.14 million, supported by an increase in government grants to USD0.10 million. Other gains and losses swung to a USD4.65 million gain (1H 2025: USD0.77 million gain) after recording the lease-related benefit, partly offset by a USD1.28 million loss on disposal of fixed assets.
Operating expenses contracted markedly: • Research and development spending fell 33% to USD2.03 million, driven by lower staff costs and reduced depreciation and amortisation. • Administrative expenses declined 16% to USD2.15 million following head-count and cost-saving measures.
Fair-value changes on RNAimmune preferred shares moved to a USD0.60 million loss (1H 2025: USD1.72 million gain). Finance costs edged down 4% to USD0.39 million.
No product revenue was booked as the company remains in the clinical stage.
Balance-sheet metrics weakened as the cash balance decreased to USD7.19 million (31 Dec 2025: USD13.52 million) after a USD6.39 million net cash outflow. Current assets fell to USD8.98 million against current liabilities of USD34.28 million, cutting the current-ratio percentage to 26.2% (31 Dec 2025: 40.3%). Net liabilities narrowed to USD21.09 million from USD24.49 million at year-end 2025.
Pipeline and strategy highlights include: • Flagship oncology candidate STP705: FDA alignment on Phase IIb/III design for squamous cell carcinoma in situ; pivotal trials targeted to commence H2 2026. • STP707 solid-tumour program paused pending partnerships; Phase I data available for due diligence. • Cardiometabolic asset STP122G completed US Phase I with favourable safety and PD signals; partnering discussions under way. • Complement and proteinopathy candidates (STP144G, STP145G, STP146G, STP152G) advance through pre-clinical stages with external collaboration sought. • Ongoing cost-optimisation and focus on oncology while out-licensing non-core programs.
Post-period events: • On 12 August 2026, the company raised approximately USD1.50 million net via a private placement of 2.44 million shares at HKD4.69 each. • On 26 August 2026, subsidiary RNAimmune agreed to sell a 5.66% stake in its vaccine arm to an external investor for RMB30.00 million, incorporating a repurchase clause tied to future milestones.
Sirnaomics indicated continued pursuit of partnership funding and selective financing to support its clinical and pre-clinical programs while managing cash runway and net-liability position.
Comments